Loading peptide profile…
Loading peptide profile…
Healing Category
THE NERVE HEALER
Cibinetide, PH-BSP
ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the helix-B region of erythropoietin. Small randomized trials in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes with painful neuropathy reported higher corneal nerve fiber area and lower neuropathic symptom scores than placebo.
People with diabetic neuropathy · Those suffering from small fiber neuropathy · Chronic pain patients · Type 2 diabetics needing nerve protection · Post-surgical healing support
Studied regimen: 4 mg SubQ once daily (7 days/week) for 28 days
28 days in the cited human studies; no automatic repeat course established.
Not medical advice.
Based on what vendors sell, not a recommendation.
Injection
Sold as vials by 82 vendors
By mouth
Not sold by vendors we track
Nasal spray
Sold as sprays by 3 vendors
No prices to compare yet
Not FDA approved, research use onlyHow we review these guides18 research sources
Taken from erythropoietin's helix-B region, the peptide is proposed to act on a receptor complex linked to tissue repair rather than the one driving red cell production.
Two small sarcoidosis neuropathy trials reported a rise in corneal nerve fiber area and more regenerating intraepidermal fibers, measured by imaging and biopsy.
In a rat nerve-injury model, treatment was linked to reduced microglial reactivity in the spinal cord alongside lasting reduction in pain behaviors.
In the type 2 diabetes trial, HbA1c and lipid values shifted favorably against placebo. This was a secondary finding rather than the question the trial set out to answer.
ARA-290 belongs to a research program that used the three-dimensional structure of erythropoietin as a starting point for designing smaller peptides. The design focuses on amino acids exposed on the helix-B surface, arranged into a short linear peptide. It is a structural design based on part of the larger protein, rather than a copy of the complete erythropoietin molecule.
[Erythropoietin structural-design study, Brines et al., 2008](https://pmc.ncbi.nlm.nih.gov/articles/PMC2504825/) · [ARA-290 structural description in an experimental study, 2022](https://pubmed.ncbi.nlm.nih.gov/36085231/)
No. This profile records ARA-290 as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
Dose: Studied regimen: 4 mg SubQ once daily (7 days/week) for 28 days. Schedule: daily. Cycle: 28 days in the cited human studies; no automatic repeat course established. This is not a clinical recommendation and does not replace individualized instructions from a licensed clinician.
This guide links to 18 curated or current research sources. Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the ARA-290 research sourcesWe don't list specific side effects for ARA-290.
ARA-290 has an editorial safety grade of B (Good Safety). Four small randomized trials, in people with sarcoidosis-associated neuropathy or type 2 diabetes with painful neuropathy, reported no serious safety signals. The human record is limited to those short trials in diagnosed patients. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
In animal studies, ARA 290 (also called PHBSP or ARA290) has been tested for recovery after nerve injury. In rats with sciatic nerve crush injury, it inhibited the early inflammatory response and promoted functional recovery. In Schwann cells in an animal study, ARA290 was reported to inhibit activation of the NLRP3 inflammasome by inhibiting NF-κB phosphorylation and reducing reactive oxygen species production.
In-stock prices from 81 vendors, checked Nov 10, 2026.
Market evidence
We found certificates from some of the ARA-290 vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
Synthetic gastric peptide studied almost entirely in animals
from $2.27/mg · 204 vendorsNº 002 / 006NNMT-blocking small molecule tested in cells and obese mice
from $0.90/mg · 121 vendorsNº 001 / 006Nine-amino-acid peptide with sparse, dated human studies
from $1.95/mg · 129 vendorsNº 003 / 006A copper binding tripeptide studied in skin and animal models
from $0.18/mg · 206 vendorsNº 004 / 006An alpha-MSH fragment studied in experimental inflammation
from $1.80/mg · 137 vendorsNº 005 / 006Mitochondrial peptide studied in mice and cells, not FDA-approved
from $1.20/mg · 203 vendorsNº 006 / 006